AstraZeneca PLC (AZN) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $204.38. It has a SharesGrow Score of 64/100, indicating a above average investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of AZN = $411.20 (+101.2% from the current price, the stock appears undervalued). Analyst consensus target is AZN = $106 (-48.4% upside).
Valuation: AZN trades at a trailing Price-to-Earnings (P/E) of 30.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.33.
Financials: revenue is $58.7B, +10%/yr average growth. Net income is $10.3B, growing at +48.3%/yr. Net profit margin is 17.5% (healthy). Gross margin is 81.9% (+9.8 pp trend).
Balance sheet: total debt is $29.7B against $48.7B equity (Debt-to-Equity (D/E) ratio 0.61, moderate). Current ratio is 0.94 (tight liquidity). Debt-to-assets is 26%. Total assets: $114.1B.
Analyst outlook: 20 / 41 analysts rate AZN as buy (49%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 29/100 (Fail), Growth 90/100 (Pass), Past 100/100 (Pass), Health 50/100 (Partial), Moat 94/100 (Pass), Future 16/100 (Fail), Income 70/100 (Pass).
